Press Enter to Main Content
您的瀏覽器似乎不支援JavaScript語法,但沒關係,這裡的JavaScript語法並不會影響到內容的陳述, 如需要選擇字級大小,IE6請利用鍵盤按住ALT鍵+ V → X → (G)最大(L)較大(M)中(S)較小(A)小,來選擇適合您的文字大小, 而IE7或Firefox瀏覽器則可利用鍵盤 Ctrl + (+)放大(-)縮小來改變字型大小,如需要回到上一頁可使用瀏覽器提供的 Alt+左方向鍵(←) 快速鍵功能,列印可使用瀏覽器提供的(Ctrl+P)功能。
  • facebook
  • line
  • twitter
  • Print
  • Back

NHRI Transfers Important Biomedical Technology to OriGem for Further Development

  • Data Source:National Health Research Institutes
  • Created:2019-06-17
  • Last Updated:2019-06-18

National Health Research Institutes (NHRI) of Taiwan is pleased to announce the licensing and transfer of two outstanding technologies — “A Microfluidic Dual-well Device for High-throughput Single-cell Capture and Culture” and “Selective Particle Transfer from One Device to Another” — to OriGem Biotech of Taiwan. The transfer of the intellectual property behind these was made official with a signing ceremony today at the Ministry of Health and Welfare in Taipei. This achievement helps reconfirm NHRI’s essential role in Taiwan’s biomedicine sector.

These two technologies were developed by a team led by Dr. Chia-Hsien Hsu of NHRI’s Institute of Biomedical Engineering and Nanomedicine. The related lines of research began in 2012 after Dr. Hsu noticed problems with monoclone culture for antibody therapy. To improve the situation, Dr. Hsu’s team designed a highly efficient cell-manipulation technique that can be used to capture single cells and subsequently culture them into monoclonal cell groups. This important finding not only was published as the cover story of the Royal Society of Chemistry’s journal Lab on a Chip in 2015 but received the National Innovation Award in 2018. By using a combination of the microfluidic dual-well device and the selective particle transfer method developed later, researchers can manipulate and culture single cells highly efficiently without expensive machines or repetitive manual operations.

OriGem Biotech is founded in 2016 that focuses on microfluidic chips for biomedicine. Since 2016, NHRI and OriGem Biotech have cooperated with each other on many projects and developed a strong working relationship.

      Successful biomedical technology transfers such as these are made possible by the government’s promotion policies and leadership of the Ministry of Health and Welfare.

Attachments